Contineum Therapeutics (CTNM) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

Strategic focus and clinical pipeline

• Focuses on neuroscience, inflammation, and immunology, with all targets starting from a neuroscience angle.

• Two clinical-stage assets: PIPE-307 (M1 receptor inhibitor, partnered with J&J) and PIPE-791 (LPA1 receptor antagonist).

• PIPE-307 is in Phase II for relapsing-remitting MS, with full enrollment expected in the first half of next year.

• J&J plans to initiate a Phase II study for PIPE-307 in depression later this year.

• PIPE-791 targets progressive MS, IPF, and pain, with multiple studies planned or underway.

PIPE-791 development and differentiation

• Phase II proof-of-concept study in IPF to start in 2025, with a robust 26-week dosing and over 100 sites.

• Progressive MS study to begin by end of 2025, focusing on imaging and functional endpoints.

• Exploratory phase 1b pain study in osteoarthritis and lower back pain is placebo-controlled and trend-seeking.

• Differentiation from competitors based on receptor occupancy, dosing regimen, and compound properties.

• PET receptor occupancy studies help optimize dosing and de-risk clinical development.

Partnership and financials

• J&J partnership for PIPE-307 includes $50M upfront, $25M crossover, IPO support, and up to $1B in milestones.

• Synthetic profit split with royalties ramping to high teens, with further increases possible upon co-development opt-in before Phase III.

• As of September, cash position was just under $215M, funding operations through 2027.